Toshiyuki Seto

Dr. Toshiyuki Seto

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in The Journal of Pediatrics
Verified
Journal Article
Open access
HSHisato Suzuki
Hisato Suzuki
MNMasatoshi Nozaki
Masatoshi Nozaki
HYHiroshi Yoshihashi
Hiroshi Yoshihashi
KIKazuo Imagawa
Kazuo Imagawa
DKDaigo Kajikawa
Daigo Kajikawa
TTToshiki Takenouchi
Toshiki Takenouchi
To delineate the diagnostic efficacy of medical exome, whole exome, and whole genome sequencing according to primary symptoms, the contribution of small copy number variations, and the impact of molecular diagnosis on clinical management. This was a prospective study of 17 tertiary care centers in Japan, conducted between April 2019 and March 2021. Critically ill neonates and infants less than 6 months of age were recruited in neonatal intensive care units and in outpatient clinics. The patients underwent medical exome, whole exome, or whole genome sequencing as the first tier of testing. Patients with negative results after medical exome or whole exome sequencing subsequently underwent whole genome sequencing. The impact of molecular diagnosis on clinical management was evaluated through contacting primary care physicians. Of the 85 patients, 41 (48%) had positive results. Based on the primary symptoms, patients with metabolic phenotypes had the highest diagnostic yield (67%, 4/6 patients), followed by renal (60%, 3/5 patients), and neurologic phenotypes (58%, 14/24 patients). Among them, 4 patients had pathogenic small copy number variations identified using whole genome sequencing. In the 41 patients with a molecular diagnosis, 20 (49%) had changes in clinical management. Genome analysis for critically ill neonates and infants had a high diagnostic yield for metabolic, renal, and neurologic phenotypes. Small copy number variations detected using whole genome sequencing contributed to the overall molecular diagnosis in 5% of all the patients. The resulting molecular diagnoses had a significant impact on clinical management.

1 January 1997 in Journal of NeuroVirology
Verified
Journal Article
Closed access
PDF file
HOHisashi Ogura
Hisashi Ogura
MAMinoru Ayata
Minoru Ayata
KHKaoru Hayashi
Kaoru Hayashi
TSToshiyuki Seto
Toshiyuki Seto
OMOsamu Matsuoka
Osamu Matsuoka
RMRyosuke Murata
Ryosuke Murata

1 March 1998 in Virus Research
Verified
Journal Article
Closed access
MAMinoru Ayata
Minoru Ayata
TKTatsuo Kimoto
Tatsuo Kimoto
KHKaoru Hayashi
Kaoru Hayashi
TSToshiyuki Seto
Toshiyuki Seto
RMRyosuke Murata
Ryosuke Murata
HOHisashi Ogura
Hisashi Ogura

Verified
Journal Article
Open access
PDF file
MMMitsuyo maeda
Mitsuyo maeda
TSToshiyuki Seto
Toshiyuki Seto
CKChiho Kadono
Chiho Kadono
HMHideto Morimoto
Hideto Morimoto
SKSachiho Kida
Sachiho Kida
HSHaruo Shintaku
Haruo Shintaku
Mucopolysaccharidosis type II (MPS II) is a rare lysosomal storage disease (LSD) involving a genetic error in iduronic acid-2-sulfatase (IDS) metabolism that leads to accumulation of glycosaminoglycans within intracellular lysosomes. The primary treatment for MPS II, enzyme replacement therapy, is not effective for central nervous system (CNS) symptoms, such as intellectual disability, because the drugs do not cross the blood–brain barrier. Recently, autophagy has been associated with LSDs. In this study, we examined the morphologic relationship between neuronal damage and autophagy in IDS knockout mice using antibodies against subunit c of mitochondrial adenosine triphosphate (ATP) synthetase and p62. Immunohistological changes suggesting autophagy, such as vacuolation, were observed in neurons, microglia, and pericytes throughout the CNS, and the numbers increased over postnatal development. Oral administration of chloroquine, which inhibits autophagy, did not suppress damage to microglia and pericytes, but greatly reduced neuronal vacuolation and eliminated neuronal cells with abnormal inclusions. Thus, decreasing autophagy appears to prevent neuronal degeneration. These results suggest that an autophagy modulator could be used in addition to conventional enzyme replacement therapy to preserve the CNS in patients with MPS II.

26 July 2015 in Molecular Cytogenetics
Verified
Journal Article
Open access
PDF file
SNSatsuki Nishigaki
Satsuki Nishigaki
THTakashi Hamazaki
Takashi Hamazaki
MSMika Saito
Mika Saito
TYToshiyuki Yamamoto
Toshiyuki Yamamoto
TSToshiyuki Seto
Toshiyuki Seto
HSHaruo Shintaku
Haruo Shintaku
Ring chromosome 6 is a rare chromosome abnormality that arises typically de novo. The phenotypes can be highly variable, ranging from almost normal to severe malformations and neurological defects. We report a case of a 3-year-old girl with mosaic ring chromosome 6 who presented with being small for gestational age and intellectual disability, and whose brain MRI later revealed periventricular heterotopia and white matter abnormalities. Mosaicism was identified in peripheral blood cells examined by standard G-bands, mos 46,XX,r(6)(p25q27)[67]/45,XX,-6[25]/46,XX,dic r(6:6)(p25q27:p25q27)[6]/47,XX,r(6)(p25q27) × 2[2]. Using array-comparative genomic hybridization, we identified terminal deletion of 6q27 (1.5 Mb) and no deletion on 6p. To our knowledge, this is the first report of periventricular heterotopia and white matter abnormalities manifested in a patient with ring chromosome 6. These central nervous system malformations are further discussed in relation to molecular genetics.

1 April 2014 in Brain and Development
Verified
Journal Article
Closed access
TSToshiyuki Seto
Toshiyuki Seto
HTHiroharu Takesada
Hiroharu Takesada
NMNaoki Matsushita
Naoki Matsushita
KIKenichi Ishibashi
Kenichi Ishibashi
NTNaohiro Tsuyuguchi
Naohiro Tsuyuguchi
HSHaruo Shintaku
Haruo Shintaku